United States Metered Dose Inhaler Devices Market Outlook to 2023

Region:North America

Author(s):

Product Code:GDMECC2509DB

Download Sample Report download
Buy the Full ReportStarting from $4995
Published on

July 2017

Total pages

41

Table of Content

Download Sample Report download
Buy the Full ReportStarting from $4995

About the Report

About the Report

United States Metered Dose Inhaler Devices Market Outlook to 2023

Summary

GlobalData's new report, "United States Metered Dose Inhaler Devices Market Outlook to 2023", provides key market data on the United States Metered Dose Inhaler Devices market. The report provides value, in millions of US dollars, volume (in units) and and average prices (USD) for Metered Dose Inhaler Devices.

The report also provides company shares and distribution shares data for each of these market segments, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular market and country, information related to pipeline products, news and deals is available in the report.

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope

Market size and company share data for Metered Dose Inhaler Devices.

Annualized market revenues (USD million) and volume (units) data for each of the market segments. Data is provided from 2009 to 2016 and forecast to 2023.

2016 company shares and distribution shares data for each of the market segments.

Global corporate-level profiles of key companies operating within the United States Metered Dose Inhaler Devices market.

Key players covered include GlaxoSmithKline Plc, AstraZeneca Plc and Boehringer Ingelheim GmbH.

Reasons to buy

Develop business strategies by identifying the key market segments poised for strong growth in the future.

Develop market-entry and market expansion strategies.

Design competition strategies by identifying who-stands-where in the market.

Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.

What are the key distribution channels and what's the most preferred mode of product distribution-Identify, understand and capitalize.

Products

Products

Drug Delivery Devices, Central Venous Catheters, Needle Free Injections, Infusion Systems, Metered Dose Inhaler Devices, Value (USD), Volume (units), Revenues, Historic Revenues, Forecast Revenues, Average Price, Company Share, Distribution Share by Revenue, Company Share by Revenue, Pipeline Products, News, Deals, Key Companies, GlaxoSmithKline Plc, AstraZeneca Plc, Boehringer Ingelheim GmbH, Pfizer Inc, Merck & Co Inc, Sunovion Pharmaceuticals Inc, Teva Pharmaceutical Industries Ltd, INJEX-Equidyne Systems, Bioject Medical Technologies Inc , Antares Pharma Inc, PharmaJet Inc, MK Global Co., The European Pharma Group, Hospira Inc, Becton Dickinson and Co, Baxter International Inc, Fresenius Kabi AG, Medtronic plc, B. Braun Melsungen AG, Terumo Corp, Smiths Medical, Nipro Corp, JMS Co Ltd


Companies

GlaxoSmithKline Plc

AstraZeneca Plc

Boehringer Ingelheim GmbH

Pfizer Inc

Merck & Co Inc

Sunovion Pharmaceuticals Inc

Table of Contents

Table of Contents

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 4

1.2 List of Figures 4

2 Introduction 5

2.1 What Is This Report About? 5

2.2 Metered Dose Inhaler Devices Market Segmentation 5

2.3 Definitions of Markets Covered in the Report 5

3 Metered Dose Inhaler Devices Market, United States 6

3.1 Metered Dose Inhaler Devices Market, United States, Revenue ($m), 2009-2016 6

3.2 Metered Dose Inhaler Devices Market, United States, Revenue ($m), 2016-2023 7

3.3 Metered Dose Inhaler Devices Market, United States, Volume (Units), 2009-2016 8

3.4 Metered Dose Inhaler Devices Market, United States, Volume (Units), 2016-2023 9

3.5 Metered Dose Inhaler Devices Market, United States, Average Price ($), 2009-2023 10

3.6 Metered Dose Inhaler Devices Market, United States, Distribution Share by Revenue ($m), 2015-2016 11

3.7 Metered Dose Inhaler Devices Market, United States, Company Share by Revenue ($m), 2016 12

4 Overview of Key Companies in United States, Metered Dose Inhaler Devices Market 14

4.1 GlaxoSmithKline Plc 14

4.1.1 Company Overview 14

4.2 AstraZeneca Plc 14

4.2.1 Company Overview 14

4.3 Boehringer Ingelheim GmbH 14

4.3.1 Company Overview 14

4.4 Pfizer Inc 15

4.4.1 Company Overview 15

4.5 Merck & Co Inc 15

4.5.1 Company Overview 15

4.6 Sunovion Pharmaceuticals Inc 15

4.6.1 Company Overview 15

5 Financial Deals Landscape 16

5.1 Debt Offerings 16

5.1.1 Merck Raises USD544 Million in Public Offering of 1.375% Notes Due 2036 16

5.1.2 Merck Raises USD544 Million in Public Offering of 0.5% Notes Due 2024 18

5.2 Venture Financing 20

5.2.1 Propeller Health Raises USD21.5 Million in Series C Financing 20

6 Recent Developments 21

6.1 Corporate Communications 21

6.1.1 Apr 10, 2017: Dr. John H. Noseworthy Nominated to Stand for Election to Merck Board of Directors 21

6.1.2 Apr 06, 2017: Merck Receives 2017 ENERGY STAR Sustained Excellence Award from U. S. Environmental Protection Agency 21

6.1.3 Mar 22, 2017: BioStable Science & Engineering Announces FDA Clearance of the HAART 300 Aortic Annuloplasty Device 21

6.2 Financial Announcements 22

6.2.1 May 31, 2017: Lamellar Biomedical Recruits First Patients into Clinical Study Assessing LAMELLEYE for Treatment of Dry Eye Disease 22

6.2.2 May 02, 2017: Merck Announces First-Quarter 2017 Financial Results 24

6.2.3 Apr 05, 2017: InVivo Therapeutics Announces New Patient Enrollment into the INSPIRE Study at the Carolinas Medical Center 26

6.2.4 Mar 29, 2017: Peer-Reviewed Clinical Study Shows ID Genomics' Bacterial Fingerprinting Technology Can Reduce Prescription Errors and Antibiotic Overuse at the Point-of-Care 26

6.2.5 Feb 02, 2017: Merck Announces Fourth-Quarter and Full-Year 2016 Financial Results 29

6.2.6 Oct 25, 2016: Merck Announces Third-Quarter 2016 Financial Results 30

6.3 Government and Public Interest 33

6.3.1 Mar 31, 2017: City Of Austin Announces Merck Economic Development Proposal 33

6.4 Other Significant Developments 33

6.4.1 Feb 21, 2017: PharmaCyte Biotech Discusses Patient Enrollment and TD2s Role in Upcoming Clinical Trial 33

6.4.2 Jan 25, 2017: Daktari Achieves Milestone in Its Merck HCV Collaboration 35

6.5 Strategy And Business Planning 35

6.5.1 Dec 01, 2016: Aptar Pharma Nears Completion Of Elastomer Component Capacity In North America 35

7 Appendix 37

7.1 Research Methodology 38

7.1.1 Coverage 38

7.1.2 Secondary Research 38

7.1.3 Primary Research 39

7.1.4 Company Share Analysis 39

7.1.5 Distribution Share Analysis 39

7.1.6 Benchmarking 40

7.2 GlobalData Consulting 40

7.3 Contact Us 41

7.4 Disclaimer 41


List of Figure

1.2 List of Figures

Figure 1: Metered Dose Inhaler Devices Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 6

Figure 2: Metered Dose Inhaler Devices Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 7

Figure 3: Metered Dose Inhaler Devices Market, United States, Volume (Units), Historic, 2009-2016 8

Figure 4: Metered Dose Inhaler Devices Market, United States, Volume (Units), Forecast, 2016-2023 9

Figure 5: Metered Dose Inhaler Devices Market, United States, Company Share (%) 2016 12


List of Table

1.1 List of Tables

Table 1: Metered Dose Inhaler Devices Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 6

Table 2: Metered Dose Inhaler Devices Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 7

Table 3: Metered Dose Inhaler Devices Market, United States, Volume (Units), Historic, 2009-2016 8

Table 4: Metered Dose Inhaler Devices Market, United States, Volume (Units), Forecast, 2016-2023 9

Table 5: Metered Dose Inhaler Devices Market, United States, Average Price ($), Historic, 2009-2016 10

Table 6: Metered Dose Inhaler Devices Market, United States, Average Price ($), Forecast, 2016-2023 10

Table 7: Metered Dose Inhaler Devices Market, United States, Distribution Share by Revenue ($m), USD Constant, 2015-2016 11

Table 8: Metered Dose Inhaler Devices Market, United States, Company Share by Revenue ($m), USD Constant, 2016 13

Table 9: Merck Raises USD544 Million in Public Offering of 1.375% Notes Due 2036 16

Table 10: Merck Raises USD544 Million in Public Offering of 0.5% Notes Due 2024 18

Table 11: Propeller Health Raises USD21.5 Million in Series C Financing 20

You can also purchase parts of this report.
Do you want to check out a section wise price list?
Get Price Break-up

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022